BioCentury
ARTICLE | Clinical News

tgAAVCF: Began Phase II trial

November 20, 2000 8:00 AM UTC

The start of the study triggered a $2 million milestone payment to TGEN from partner Celltech Group plc (LSE:CCH; CLL, Slough, U.K.). ...